ENA Respiratory
Melbourne, Australia
◆ Total Raised
$3M
◆ Location
Melbourne, Australia
◆ Founded
2020
◆ Team size
11-50
◆ Links
◆ About ENA Respiratory
Clinical-stage biotech developing antiviral nasal spray treatments for respiratory viruses.
◆ What sets it apart
Its lead asset is a virus-agnostic, self-administered nasal prophylactic that boosts the body’s innate immune defense rather than targeting a specific virus.
◆ Sectors
◆ Business
Modelhardware
CustomerAt-risk individuals and populations vulnerable to respiratory viral complications, including older adults, people with comorbidities, and occupationally exposed groups
◆ Notable
- Founded as an independent company in 2020
- Advanced INNA-051 as a clinical-stage nasal prophylactic
- Raised multiple financing rounds, including a reported US$22.4 million Series B in 2025
- Received funding from the Gates Foundation, Flu Lab, Brandon Capital, Uniseed, Stoic Venture Capital, and the Minderoo Foundation
- Entered a partnership with the COPD Foundation to develop INNA-051 for people with chronic lung disease
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does ENA Respiratory do?
Clinical-stage biotech developing antiviral nasal spray treatments for respiratory viruses.
Where is ENA Respiratory based?
ENA Respiratory is based in Melbourne, Australia, founded in 2020.
How much has ENA Respiratory raised?
ENA Respiratory has raised $3M in tracked funding.
Who has invested in ENA Respiratory?
Investors in ENA Respiratory include Brandon Capital, Uniseed, Minderoo Foundation, Gates Foundation, Flu Lab and Stoic Venture Capital.